SCHEMBL23613747

SCHEMBL23613747

CC(=O)NC1C(OC(C)(C)C)OC(CO)C(OC2OC(CO)C(O)C(OC3OC(CO)C(O)C(O)C3O)C2O)C1O

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 6/20 0.61
▸ LGALS8 O00214 1/20 0.61
▸ LGALS4 P56470 1/20 0.61
▸ CD69 Q07108 1/20 0.48
▸ CHIA Q9BZP6 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ LGALS1 P09382 1/20 0.47
▸ LGALS7; LGALS7B P47929 1/20 0.47
▸ MAPK1 P28482 2/20 0.46
▸ LGALS9 O00182 1/20 0.46
▸ FGF1 P05230 1/20 0.43
▸ FGF2 P09038 1/20 0.43
▸ VEGFA P15692 1/20 0.43
▸ HPSE Q9Y251 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20998797 0.92 LGALS3 (0.55) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL18122370 0.89 LGALS3 (0.66) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL13663185 0.88 LGALS3 (0.60) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL13663197 0.88 LGALS3 (0.62) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL26334737 0.88 LGALS3 (0.64) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL23613765 0.88 LGALS3 (0.64) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL24004014 0.87 LGALS3 (0.66) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL21258444 0.87 LGALS3 (0.66) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL24003672 0.87 LGALS3 (0.66) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL22193218 0.87 LGALS3 (0.63) LGALS3LGALS8LGALS4CD69CHIA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11052141-B1 Method of modifying the immune response KODE BIOTECH LIMITED (NZ) 2021-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052141-B1 Method of modifying the immune response HLA-C, CD74, HLA-DRB1 LGALS3 107/4885LGALS8 135/4885LGALS4 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback